BSH 2017 | TAP funded Tier study for relapsed and refractory CNS lymphoma patients
Christopher Fox, MBChB, MRCP, FRCPath, from Nottingham University Hospital, Nottingham, UK discusses the Tier study at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. The therapy accelerated program (TAP), sponsored by the charity Bloodwise, funds early phase studies for patients with all blood cancers. Dr Fox is a chief investigator for a TAP funded study, Tier, a phase I/II trial investigating the use of immunochemotherapy drugs, such as thiotepa, in patients with relapsed and refractory primary CNS lymphoma who failed first-line treatment. Although it will be a couple of years before these results will be analysed, it is important to generate data even in rare patient groups. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
